Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 1998, p. 958-964, Vol. 36, No. 4
Albany Medical College, Albany, New York
122081;
Rush Presbyterian St. Luke's
Medical Center, Chicago, Illinois
60153-38332;
Food and Drug
Administration, Bethesda, Maryland 208923;
University of Texas Medical Branch, Galveston, Texas
77555-08354;
Northwestern University
Children's Memorial Hospital, Chicago, Illinois
606145;
Newton, Massachusetts
021656;
University of Colorado Medical
Center, Denver, Colorado 802627;
National Institutes of Health, Bethesda, Maryland
20892-76208; and
Beth
Israel-Deaconess Medical Center, Boston, Massachusetts
02215-54009
Received 27 August 1997/Returned for modification 17 November
1997/Accepted 5 January 1998
A flow cytometric assay has been developed for the measurement of
susceptibilities to ganciclovir of laboratory strains and clinical
isolates of human cytomegalovirus (HCMV). The assay uses fluorochrome-labeled monoclonal antibodies to HCMV immediate-early and
late antigens to identify HCMV-infected cells and flow cytometry to
detect and quantitate the number of antigen-positive cells. By this
assay, the 50 and 90% inhibitory concentrations (IC50 and
IC90, respectively) of ganciclovir for the AD169 strain of HCMV were 1.7 and 9.2 µM, respectively, and the IC50 for
the ganciclovir-resistant D6/3/1 derivative of the AD169 strain was
greater than 12 µM. The ganciclovir susceptibilities of 17 HCMV
clinical isolates were also determined by flow cytometric analysis of
the effect of ganciclovir on late-antigen synthesis in HCMV-infected
cells. The average IC50 of ganciclovir for drug-sensitive
HCMV clinical isolates was 3.79 µM (±2.60). The plaque-reduction
assay for these clinical isolates yielded an average IC50
of 2.80 µM (±1.46). Comparison of the results of the flow cytometry
assays with those obtained from the plaque-reduction assays
demonstrated acceptable bias and precision. Flow cytometric and
plaque-reduction analysis of cells infected with ganciclovir-resistant
clinical isolates failed to show a reduction in the percentage of
late-antigen-positive cells or PFU, even at 96 µM ganciclovir. The
flow cytometric assay for determining ganciclovir susceptibility of
HCMV is quantitative, and objective, and potentially automatable, and
its results are reproducible among laboratories.
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Flow Cytometric Determination of Ganciclovir
Susceptibilities of Human Cytomegalovirus Clinical Isolates
*
Corresponding author. Mailing address: Department of
Microbiology, Immunology, and Molecular Genetics, A-68, Albany Medical College, 47 New Scotland Ave., Albany, NY 12208. Phone: (518) 262-5174. Fax: (518) 262-5748. E-mail:
jim_mcsharry{at}ccgateway.amc.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»